Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
In the citing paper
“Clearly, molecular weight is a physicochemical parameter fundamental for CNS penetration and for the overall profile of drugs against neurodegenerative diseases.103,104”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Self-citationPhysiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Self-citationCNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Self-citationGhose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Development of a new permeability assay using low‐efflux MDCKII cells
Di, L., Whitney‐Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22674 · Cited by 313
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Ertl, P. (2007) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621286.ch5 · Cited by 75
Research works printed but not linked: 1
- Harrington, E. C., Jr. (1965) The desirability function. Indust. Qual. Control 21, 494-498.
Cited by
Items 601–700 of 746
Schlein, E., Rokka, J., Odell, L. R., van den Broek, S. L., Herth, M. M., Battisti, U. M., Syvänen, S., Sehlin, D., & Eriksson, J. (2024) · Figshare · doi:10.6084/m9.figshare.25357773
EVALUATING NATURAL PRODUCT LIBRARIES WITH EMPHASIS ON IN VITRO PERMEABILITY WORKFLOWS
Kirk, R. D. (2021) · Digital Commons - URI (University of Rhode Island)
Furiassi, L. (2019) · CINECA IRIS Institutional Research information system (University of Urbino)
Zerroug, E. (2020) · University of Biskra Theses Repository (University of Biskra)
Distribution of DNA Damage Response Inhibitors to the Central Nervous System for Brain Tumor Therapy
Talele, S. (2022) · University of Minnesota Digital Conservancy (University of Minnesota)
Gábor, G. (2024) · SZTE Repository of Dissertations (University of Szeged)
Design, Synthesis and Evaluation of Aromatic Carbamates as Neuroprotective Agents
Kinarivala, N. (2018) · ThinkTech (Texas Tech University)
Molecular Dynamics in Predicting the Stability of Drug-Receptor Interactions
Chen, S., & Zacharias, M. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_27
Bueno, M. D. M. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Inibição in silico de SARS-CoV-2 e CHIKV por derivados de fenóis e cromonas
Lima, J. P. O. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Nunes, J. V. S. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Barbosa, I. M., Ferreira, M. K. A., da Silva, A. W., Mendes, F. R. D. S., Rebouças, E. D. L., Marinho, M. M., Marinho, E. S., Santos, F. A., Nunes, P. I. G., Guedes, M. I. F., et al. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100231
Tailoring cariprazine for dual disorders via secondary pharmacophore optimization
Vogt, C. D., Sanchez, J., Bonifazi, A., Saab, E., Ranjit, A., Rais, R., Lane, J. R., & Newman, A. H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118654
Nandy, A. K., Phukan, S., & Ramarao, M. K. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15000032/v1
Angel, G., & Sujatha, P. L. (2026) · International Conference on Mobile Computing and Sustainable Informatics (ICMCSI) · doi:10.1109/icmcsi67283.2026.11412406
“Finally, CNS-active filtering was performed utilizing the multiparameter optimization score (CNS-MPO) [25]: CNS-MPO=f(cLogP, cLogS, MW, TPSA, HBD, pKa) (2) Where cLogP describes lipophilicity, cLogS reflect solubility, MW denotes molecular weight, TPSA represents polarity, HBD indicates…”
Borges, E. D. L. R., da Silva, A. W., Moreira, E. P. A., da Rocha, M. N., dos Santos, H. S., de Menezes, J. F. S., da Fonseca, A. M., Guedes, M. I. F., & Marinho, E. S. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71141
Morais, G. R., Nwokolo, G. C., Mills, H. N. L., Wheelhouse, R. T., & Falconer, R. A. (2026) · Molecules · doi:10.3390/molecules31071103
“The CNS multiparameter optimisation (CNS MPO) scores for these prodrugs ranged between 4.0 and 4.9, indicating that they have the potential to cross the blood–brain barrier (BBB) [47].”
InfluentialFlow-chemistry methods in the search for new 2-arylpyrrole derivatives as 5-HT6 receptor ligands.
Drop, M. (2021) · theses.fr (ABES) · doi:10.70675/bf76018ez6709z422bz87b5zbb751425f5ae
Rosenstock, T. R., Ohzeki, H., Kumagai, S., Suda, N., & Smith, C. S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104671
Feitosa, C. R. D. S., Silva, J. A. D., Maciel, J. B., Romão, I. C., Cavalcante, T. R., Barros, F. A. N., Bandeira, N. D. A., Marinho, E. S., de Menezes, J. E. S. A., Ferreira, M. K. A., et al. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.202502272
“…(TPSA) descriptors were aligned, it was possible to observe that the compound resides in a physical chemical space formed by CNS-active compounds with a low toxic response in vivo (Figure 8C ), according to the Pfizer, Inc. biopharmaceutical classification system (TPSA 75-120 Å2) [ 60, 61 ].”
Reyes, S. T., Kuo, R., Jackson, I. M., Kalita, M., Mahn, P., Mak, S., Sundar, M., Zhang, B., Green, J., Chan, H.-W., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9374449/v1
PET and SPECT isotopes: Basic radiochemistry, new trends, and applications in molecular imaging
Schou, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-19154-1.00011-2
Rysanek, D., Chrienová, Ž., Stary, D., Bajda, M., Novak, J., Vašicová, P., Kroupová, J., Andrýs, R., Skarka, A., Roušarová, E., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04308-0
Muñoz-González, F., Bello, M., Correa‐Basurto, J., & Bandala, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115024
“Although docking scores should be interpreted cautiously and do not constitute direct evidence of biological activity, the results suggest that nucleoside-related scaffolds may be capable of establishing stabilizing interactions within the PD-L1 homodimer binding interface [38].”
Sumathi, S., Nallasamy, K., & Jeyavijayan, S. (2026) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2026.05.005
dos Reis, C. R. C., de Souza, H. V. C. M., Parra, L. C., de Souza, G. V. C. M., Zorzanelli, B. C., Boechat, N., Hoelz, L. V. B., & Fernandes, T. V. A. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70340
“Similarly, the CNS MPO desirability tool demonstrated that deliberate navigation of property space increased clinical candidate survival by shifting design towards less lipophilic chemical matter whilst maintaining adequate target engagement (Wager et al. 2016).”
New N-Arylpiperazine-Based Compounds as Potential Inhibitors of Purinergic P2X7-Associated Signaling
Greifová, G., Dubničková, M., Nádaská, D., Šándrik, R., Kapustíková, I., Švajdlenka, E., Pisárčik, M., Csöllei, J., & Malík, I. (2026) · Life · doi:10.3390/life16071046
Improving the Pharmacokinetics of Radiopharmaceuticals
Herth, M. M., & Battisti, U. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-26476-3_29
Artificial Intelligence and Other Emerging Technologies for Radiopharmaceutical Development
Bowden, G. D., Webb, E., Jackson, I. M., James, M. L., & Scott, P. J. H. (2026) · Springer eBooks · doi:10.1007/978-3-032-26476-3_36
Seomun, S., & Yoo, S. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0184
“5 D to F) [ 56 , 57 ].”
BBB-Nuke: Transport-Aware Prediction of Blood-Brain Barrier Penetration in Small MoleculesPreprint
Abasciano, N., Hadipour, H., Poddar, A., Rudrum, J., & Sobodu, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.13.738280
“The CNS Multiparameter Optimization (CNS-MPO) framework, introduced by Wager et al. at Pfizer [Wager et al., 2010, 2016], maps six molecular properties (molecular weight, cLogP, TPSA, HBD, pK a , cLogD) to desirability scores and sums them into a composite score ranging from 0 to 6.”
InfluentialMachine Learning in Predicting the Physicochemical Properties of Drug Candidates
Nuthi, A., & Dixit, V. A. (2026) · Royal Society of Chemistry eBooks · doi:10.1039/9781837070206-00280
Filho, J. I. L. P., Lúcio, F. N. M., Ribeiro, L. R., da Rocha, M. N., dos Santos, H. S., Almeida-Neto, F. W. Q., Magalhães, E. P., Martins, A., de Menezes, R. R. P. P. B., Marinho, M. M., et al. (2026) · ACS Omega · doi:10.1021/acsomega.5c08163
A novel small molecule remyelination therapy for multiple sclerosis
Yang, Y., Bai, B., Knutsen, L. J. S., Hamlyn, R. J., Cui, Q., Antel, J. P., Macklin, W. B., Medicetty, S., & Trapp, B. D. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00060-7
“The ChemBridge Library of 20,000 CNS-biased small molecules was chosen because it was designed to be enriched in brain-penetrable small molecules using Multiparameter Optimization (MPO) scoring 39 .”
Reichert, L., Delparente, A., Hipfinger, I. R., Reininger, L., Castro, A. P., Hubin, D. J., Schibli, R., Fraley, A. E., & Mu, L. (2026) · ChemMedChem · doi:10.1002/cmdc.70399
“This system ranks compounds on a scale from 0 to 6, where a higher CNS MPO value aligns with increased BBB permeability [26].”
de Sousa, D. S., Belarmino, A. B., de Sousa, H. M. A., da Silva, R. G., Marinho, M. M., da Fonseca, A. M., & Marinho, G. S. (2026) · Chemical Papers · doi:10.1007/s11696-026-05192-8
“The joint evaluation of these six properties (N = 6) provides a total score ranging from 0 to 6 (Hughes et al. 2008; Wager et al. 2016).”
Rahman, N. F., & Agus, W. (2026) · Journal Of Tropical Pharmacy And Chemistry · doi:10.30872/jtpc.v10i2.402
“Furthermore, lipophilicity is a crucial parameter in the development of drugs that act on the central nervous system because it is related to the molecule's ability to penetrate the blood-brain barrier (BBB) [21], [27].”
Silverman, R. B., Xue, F., & Juncosa, J. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15862-9.00003-5
Prapa, P. M., Saba, A. A., Hosen, M. R., Bhattacharjee, P., Majumder, B. K., Palit, P., Guinto, M. C., & Sarker, P. K. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100529
Shen, L., Chen, Z., Huan, W., Huang, Y., Wu, P., Guo, H., Zhang, C., & Zhuang, S. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.6c06459
Saffour, S., Gül, T. S., & Gul, H. I. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2714022
Interpretable Prediction of Ligand–Protein Binding without Protein Structural Information
Sadagopan, A., Sodhi, A., & Gibson, W. J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00249
Rivara, M., Malacrida, A., Ghizzi, M., Bentivegna, A., Sica, F. S., Re, F., Motta, S., Callea, L., Bonati, L., Incerti, M., et al. (2026) · Biology · doi:10.3390/biology15161371
Boudouda, H. B., Mennana, I., Krid, A., İşci, R., Sehout, I., Bensouissi, C., Boulcina, R., Öztürk, T., & Debache, A. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147336
Júnior, E. G. D. S., Dantas, I. G. P., Lourenço, M. D. S., Borges, J. A. D. O., Araújo, I. M., Silva, J. T. D. C., de Araújo, A. C. J., Freitas, P. R., Rocha, J. E., Leandro, M. K. D. N. S., et al. (2026) · Antibiotics · doi:10.3390/antibiotics15080794
“…available central nervous system (CNS)-active drugs (TPSA > 75 Å 2 ) exhibit favorable in vitro ADMET properties, including high passive permeability (Papp > 10 × 10 − 6 cm/s), low intestinal P-glycoprotein-mediated efflux, and low intrinsic hepatic clearance (CLintu 100 mL/min/kg) [33].”
Ashakin, M. R., Stuetzle, C. S., Haider, M. R., Khan, R. I., & Roosan, D. (2026) · Computational and Structural Biotechnology Reports · doi:10.34133/csbr.0010
Filho, M. A. C. D. O., Silva, J., de Oliveira, V. M., de Sousa, D. S., da Rocha, M. N., Marinho, M. M., & Marinho, E. S. (2026) · Journal of Molecular Modeling · doi:10.1007/s00894-026-06924-z
Li, M., Zhang, S., Powell, A. B., Stewart, H. C., Ourlian, L. N., Roest, S. V., Alt, A. J., Rech, J. C., White, A. D., & Traynor, J. R. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00303
Phukan, S., Nandy, A. K., & Ramarao, M. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00347
Nagashima, Y. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00496
Oluyemi, W. M., Eze, S. C., Nnemolisa, S. C., Adeniyi, A. T., Mosebi, S., & Okagu, I. I. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15009348/v1
Simić, S., Łażewska, D., Kalaba, P., Wackerlig, J., & Langer, T. (2026) · Membranes · doi:10.3390/membranes16100315
“Because the model uses a calculated logP descriptor together with IAM retention measured at pH 5.5, direct intestinal-permeability and pH-dependent distribution studies are required before concluding that the compounds are orally absorbed [48,54,63].”
Influentialda Silva, L., de Morais, N. M., Rodrigues, E. Y. D. S., Gonçalves, S. A., de Araújo, G. A., Rocha, J. E., de Freitas, T. S., Tintino, C. D. M. O., Tintino, S. R., Bandeira, P. N., et al. (2026) · ChemistrySelect · doi:10.1002/slct.74646
In Silico Drug-Likeness, ADMET, and Toxicity Profiling of Phytochemicals from Annona squamosa
Bello, A. T., Alhaji, I., Magaji, Y., Emmanuel, E., Abdulsalami, S. M., Hassan, A. U., Ozojiofor, U. O., & Salisu, N. (2026) · UMYU Scientifica · doi:10.56919/usci.2654.010
“While favorable for CNS targets, for peripheral prostate cancer therapy, high CNS penetration may be undesirable due to potential off – target effects and tissue sequestration (Norinder & Haeberlein, 2002; Pajouhesh & Lenz, 2005; Wager et al ., 2016).”
Nicol, N. I., Li, T., Su, Q., Suhocki, A., Dunlap, E., 周雪艳, Jester, H. M., Swift, N. A., Underwood, E. B., Lee, J., et al. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70563
Simić, S., Leuci, R., Pirker, M., Kalaba, P., Wackerlig, J., Piemontese, L., & Langer, T. (2026) · ACS Omega · doi:10.1021/acsomega.6c07555
Sharma, V., Patel, K. K., Vaishnav, B., Patel, K. K., Porwad, D., & Jagan, H. (2026) · International Journal of Engineering Science and Generic Research
Iring, A., Kiss, D. J., Baranyi, M., Gal, Z. T., Herczku, E., Tod, P., Egyed, A., Demeter, K., von Kügelgen, I., Wu, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.02.756181
“During candidate prioritization, BBB penetration potential was estimated by calculating CNS multiparameter optimization (CNS MPO) scores according to Wager et al. [43] and BBB scores as described by Gupta et al. [44].”
Coumarin‐Benzimidazole Hybrids as Multitarget Scaffolds for Antileishmanial Drug Discovery
Jucá, F. M., de Sousa, D. S., Roberto, C. H. A., Marinho, M. M., & Marinho, E. S. (2026) · ChemistrySelect · doi:10.1002/slct.74741
Jahan, K., Bonifazi, A., Sanchez, J., Saab, E., Jackson, S. N., Tressler, E. H., Cymek, K. S., Vendruscolo, J. C. M., Bi, G.-H., Maras, M., et al. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00333
He, L., Zhang, Q., Ma, W., Qian, M., Dong, Y., Xin, F., Guo, C., 曹国锐, Tuo, F., & Huang, L. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110668
Gemki, M., Wunderlich, L., Köhler, L., Neumaier, F., Endepols, H., Zlatopolskiy, B. D., Neumaier, B., & Zempel, H. (2026) · Cells · doi:10.3390/cells15212033
BindingDB (2021) · UC San Diego · doi:10.7270/q21c219x
BindingDB Entry 50001237: The discovery of VU0486846: steep SAR from a series of M
BindingDB (2020) · UC San Diego · doi:10.7270/q2qr50n4
BindingDB (2023) · UC San Diego · doi:10.7270/q2ws8z41
BindingDB Entry 50015301: Novel Dual-Target μ-Opioid Receptor and Dopamine D
BindingDB (2023) · UC San Diego · doi:10.7270/q2n301v5
BindingDB Entry 50000913: Towardβ-Secretase-1 Inhibitors with Improved Isoform Selectivity.
BindingDB (2020) · UC San Diego · doi:10.7270/q2tx3hvx
BindingDB (2022) · UC San Diego · doi:10.7270/q25b066s
BindingDB Entry 50015387: Discovery of (
BindingDB (2023) · UC San Diego · doi:10.7270/q2x63rt2
BindingDB Entry 50020610: Dopamine D
BindingDB (2024) · UC San Diego · doi:10.7270/q2m90f4g
BindingDB Entry 50002881: VU6007477, a Novel M
BindingDB (2020) · UC San Diego · doi:10.7270/q2rj4n44
BindingDB (2023) · UC San Diego · doi:10.7270/q2ww7nqk
BindingDB (2024) · UC San Diego · doi:10.7270/q2pz5f50
BindingDB (2024) · UC San Diego · doi:10.7270/q2v98dh6
BindingDB (2025) · UC San Diego · doi:10.7270/q2xk8m7g
BindingDB Entry 50007001: Overview of Recent Strategic Advances in Medicinal Chemistry.
BindingDB (2021) · UC San Diego · doi:10.7270/q2br8wfx
BindingDB Entry 50000832: Discovery of a novel, CNS penetrant M
BindingDB (2020) · UC San Diego · doi:10.7270/q2kp84mj
Metadata
- Authors
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Wager, Travis T.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-03-18
- Volume
- 7
- Issue
- 6
- Pages
- 767-775
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2300160852
- Cited by
- 653
- References
- 13
- Citations by year
- 2026: 104 · 2025: 121 · 2024: 103 · 2023: 75 · 2022: 72 · 2021: 45 · 2020: 37 · 2019: 32 · 2018: 40 · 2017: 19 · 2016: 5
- FWCI
- 30.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- desirability function, drug candidate design, ADME properties, blood-brain barrier permeability, ClogP, topological polar surface area, drug safety, drug discovery
- MeSH terms
- Algorithms, Animals, Biological Transport, Blood-Brain Barrier, Central Nervous System, Humans, Permeability, Drug Design, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.